| Literature DB >> 30429697 |
Mark John-Yung Lin, Megan Rose Paul, Dennis John Kuo.
Abstract
Vincristine is a chemotherapeutic agent with a potential toxicity of sensorimotor peripheral neuropathy. Patients receiving chemotherapy are in an immunocompromised state and may require antifungal agents. Triazole antifungals are known inhibitors of cytochrome P450 (CYP) enzymes. Vincristine is a known CYP3A4 and CYP3A5 substrate, and concomitant administration with fluconazole or voriconazole has been reported to increase vincristine toxicity and peripheral neuropathy, but there is limited literature on posaconazole in this regard. This 5-year-old girl with pre-B-cell acute lymphoblastic leukemia received vincristine while receiving posaconazole for a mucormycosis infection and developed unexpectedly severe peripheral neuropathy. After recovery, the child continued on mucormycosis prophylaxis with posaconazole with instructions to hold for 2 days before and on the day of vincristine administration. This case illustrates the potentiating effect that posaconazole had on vincristine-associated neurotoxicity, and our approach to mitigating that negative interaction.Entities:
Keywords: CYP3A4; leukemia; neurotoxicity; posaconazole; vincristine
Year: 2018 PMID: 30429697 PMCID: PMC6213623 DOI: 10.5863/1551-6776-23.5.417
Source DB: PubMed Journal: J Pediatr Pharmacol Ther ISSN: 1551-6776